TREVIAMET

This brand name is authorized in Nigeria.

Active ingredients

The drug TREVIAMET contains a combination of these active pharmaceutical ingredients (APIs):

1	Metformin UNII 786Z46389E - METFORMIN HYDROCHLORIDE
	Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.
	Read more about Metformin
2	Sitagliptin UNII QFP0P1DV7Z - SITAGLIPTIN
	Sitagliptin is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors. The improvement in glycaemic control observed with this medicinal product may be mediated by enhancing the levels of active incretin hormones.
	Read more about Sitagliptin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-2084	Tablet	Treviamet 50 mg + 1000 mg Tablets TAB 1000 mg; 50 mg	Each tablet contains: Metformin Hydrochloride 1000 mg, Sitagliptin 50 mg	30/11/2020

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BD07	Metformin and sitagliptin	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BD Combinations of oral blood glucose lowering drugs
Discover more medicines within A10BD07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-0344, B4-2084